Introduction
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most common nosocomial pathogens, and resistant to most β-lactam antibiotics and even new antimicrobials, which has compelled clinicians to resort to some "old" antimicrobial agents ([@B4]). Fosfomycin, which was first discovered in *Streptomyces* sp. in 1969, possesses broad-spectrum activity against both Gram-positive and Gram-negative bacteria by inhibiting bacterial cell wall synthesis ([@B16]). Specifically, fosfomycin deactivates the enzyme UDP-*N*-acetylglucosamine-3-enolpyruvyltransferase, also known as MurA (encoded by the *murA* gene), thereby irreversibly interfering with the first committed step of peptidoglycan biosynthesis ([@B16]). In recent years, the administration of fosfomycin alone or in combination with other antibiotics has been prescribed for treatment of MRSA ([@B10]; [@B5]; [@B17]). However, fosfomycin-resistant *S. aureus* strains have continued to emerge and increase ([@B7]). In China, the fosfomycin resistance rate in MRSA was as high as 29.5% in 2010 ([@B13]).

Bacterial fosfomycin resistance is attributed both to the acquisition of chromosomal mutations and to the expression of plasmid-encoded fosfomycin-modifying enzymes. Mutations in *murA* have been shown to reduce the affinity of fosfomycin for MurA ([@B14]). Additionally, fosfomycin intake can be reduced in the presence of mutations in *glpT* and/or *uhpT*, which encode fosfomycin transport systems of bacteria ([@B18]; [@B16]). Lastly, fosfomycin activity can be inhibited via the catalytic activity of FosA, FosB, FosC, and FosX, respectively ([@B12]; [@B11]; [@B15]). Meanwhile, of the known plasmid-mediated fosfomycin resistance genes, only *fosB* has been detected in *Staphylococcus* sp. To date, however, most researches have focused on fosfomycin-resistant Gram-negative bacteria, and relatively few studies have been conducted in fosfomycin-resistant Gram-positive bacteria ([@B16]). The purpose of this study was to investigate the prevalence fosfomycin resistance and mutations in the *murA, glpT*, and *uhpT* genes in fosfomycin-resistant MRSA strains isolated in China.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

A total of 96 MRSA clinical strains were isolated from blood or cerebrospinal fluid specimens at Huashan hospital, a teaching hospital in Shanghai, China, between 2004 and 2014. *S. aureus* ATCC 29213 (American Type Tissue Culture Collection, Manassas, VA, USA) was used as a quality control strain in antimicrobial susceptibility testing experiments.

Antimicrobial Susceptibility Testing
------------------------------------

The minimum inhibitory concentration (MIC) of fosfomycin for each clinical strain was determined by agar dilution supplemented with Glucose-6-phosphate (25 mg/L), according to the recommendations of the Clinical and Laboratory Standards Institute ([@B3]), and results were interpreted according to European committee on antimicrobial susceptibility testing criteria ([@B8]) (susceptible, ≤32 mg/L; resistant, ≥64 mg/L).

PCR Amplification
-----------------

DNA of 96 MRSA strains was harvested using TIANamp bacteria DNA Kit (Tiangen, Beijing, China). The presence of the *fosA, fosB*, and *fosC*, was detected by PCR as described previously ([@B2]). *murA, glpT* and *uhpT* genes are amplified by PCR using primers listed in **Table [1](#T1){ref-type="table"}**. The PCR products were sequenced to screen for mutations.

###### 

PCR primers of *fosA, fosB, fosC, murA, glpT* and *uhpT* gene.

  ---------------------------------------------------------------------------------
  Primers   Gene     Primer sequences (5′ \> 3′)   Product size   Reference
  --------- -------- ----------------------------- -------------- -----------------
  fosA-F\   *fosA*   GCTGCACGCCCGCTGGAATA\         217 bp         [@B2]
  fosA-R             CGACGCCCCCTCGCTTTTGT                         

  fosB-F\   *fosB*   CAGAGATATTTTAGGGGCTGACA\      312 bp         [@B2]
  fosB-R             CTCAATCTATCTTCTAAACTTCCTG                    

  fosC-F\   *fosC*   GGGTTACATGCCCTTGCTCA\         354 bp         [@B2]
  fosC-R             AACCCGCACAACGACAGATG                         

  murA-F\   *murA*   GCCCTTGAAAGAATGGTTCGT\        1600 bp^∗^     NC_002745.2^∗∗^
  murA-R             GTTACAATACTCGACGCAGGT                        

  glpT-F\   *glpT*   TGAATAAAACAGCAGGGCAA\         1699bp^∗^      NC_002745.2^∗∗^
  glpT-R             CACAGCTAGTATGTATAACGAC                       

  uhpT-F\   *uhpT*   TGTGTTTATGTTCAGTATTTTGGA\     1571 bp^∗^     NC_002745.2^∗∗^
  uhpT-R             TCTTTCATCTCTTCACGCAC                         
  ---------------------------------------------------------------------------------

∗

PCR product including surrounding sequences adjacent to target gene.

∗∗

GenBank-EMBL-DDBL accession number.

Multilocus Sequence Typing (MLST)
---------------------------------

*Staphylococcus aureus* sequence types (STs) were determined by comparing the sequences of the housekeeping genes *arcC, aroE, glp, gmk, pta, tpi*, and *yqiL*, as described previously ([@B6]), with those in the MLST database available at <http://saureus.mlst.net/> ([@B1]).

Nucleotide Sequence Accession Numbers
-------------------------------------

The sequences for the TypeA*~murA~*, TypeI*~murA~*, TypeII*~murA~*, TypeIII--VI*~murA~*, TypeA--E*~glpT~*, TypeI*~glpT~*, TypeII*~glpT~*, TypeIII*~glpT~*, TypeVI*~glpT~*, TypeV*~glpT~*, and TypeA--H*~uhpT~* strains have been deposited in GenBank with the following accession numbers: KT372186, KT372187, KT372185, KT372188--KT372191, KT372192--KT372196, KT372197, KT372198, KT372201, KT372199, KT372200, and KT372202--KT372209, respectively.

Results
=======

Fosfomycin Susceptibility
-------------------------

The MICs of fosfomycin for the MRSA strains ranged from 1.0 mg/L to \>1,024 mg/L. Furthermore, MIC~50~ and MIC~90~ values of these strains were 1,024 mg/L and \>1,024 mg/L, respectively. According to the EUCAST criteria, 67 out of the 96 examined MRSA isolates were characterized as fosfomycin-resistant (MIC ≥ 64 mg/L).

Prevalence of Fosfomycin Resistance Genes
-----------------------------------------

Of the 96 MRSA isolates, 9 fosfomycin-resistant strains with MIC ≥ 128 mg/L contained *fosB* (**Table [2](#T2){ref-type="table"}** and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}), and no isolates were positive for *fosA* and *fosC*.

###### 

Characteristics of 96 methicillin-resistant *Staphylococcus aureus* isolates.

  MLST types   Strain No.   *fosB* gene   Mutation in *glpT* alone   Mutation in *uhpT* alone   Mutation in both *glpT* and *uhpT*   No mutation in *glpT* and *uhpT*                              
  ------------ ------------ ------------- -------------------------- -------------------------- ------------------------------------ ---------------------------------- ---- ---------------- ---- ----------
  ST5          40           Negative      4                          64 \~ \> 1024              6                                    128 \~ \>1024                      30   1024 \~ \>1024   0    --
  ST239        34           Negative      2                          128                        2                                    128 \~ \>1024                      5    1024 \~\>1024    25   1 \~ 256
  ST6          1            Negative      0                          \-                         0                                    \-                                 0    \-               1    1
  ST30         1            Negative      1                          2                          0                                    \-                                 0    \-               0    --
  ST59         4            Negative      4                          1                          0                                    \-                                 0    \-               0    --
  ST88         1            Negative      0                          \-                         0                                    \-                                 0    \-               1    1
  ST121        1            Negative      1                          2                          0                                    --                                 0    \-               0    --
  ST398        1            Negative      1                          1                          0                                    \-                                 0    \-               0    --
  ST764        3            Negative      0                          \-                         3                                    256 \~ 512                         0    \-               0    --
  ST863        1            Negative      0                          \-                         0                                    \-                                 0    \-               1    32
  ST5          6            Positive      1                          512                        2                                    \>1024                             3    \>1024           0    --
  ST239        1            Positive      0                          \-                         0                                    \-                                 0    \-               1    128
  ST764        1            Positive      0                          \-                         0                                    \-                                 1    \>1024           0    --
  ST2590       1            Positive      1                          \>1024                     0                                    \-                                 0    \-               0    --

Mutations in the *murA* Gene
----------------------------

Seven distinct mutations were detected in the *murA* gene of the 96 MRSA isolates. Mutation TypeA*~murA~*, which resulted in the creation of a stop codon (TA~125~A) at position 42 and a possible new start codon was found at position 94 (**Figure [1](#F1){ref-type="fig"}**), was contained by one of the fosfomycin-resistant MRSA isolates. In contrast, the other six mutations (TypeI--VI*~murA~*), which resulted in distinct amino acid substitutions within the MurA protein, could be found in fosfomycin-sensitive MRSA isolates, though one mutation (TypeII*~murA~*) also could be found in fosfomycin-resistant MRSA isolates. (**Table [3](#T3){ref-type="table"}**).

![**Types and positions of mutation in *murA, glpT*, and *uhpT* genes.** TypeA*~murA~* (KT372186): T125A (Result in a possible start codon in position 94th aa); TypeI*~murA~* (KT372187): G193C; TypeII*~murA~* (KT372185): G770A; TypeIII*~murA~* (KT372188): C834A; TypeIV*~murA~* (KT372189): A873T; TypeV*~murA~* (KT372190): A1085G; TypeVI*~murA~* (KT372191): CG1187-1188AT. TypeA*~glpT~* (KT372192): Deletion of 8bp from 225T to 232A; TypeB*~glpT~* (KT372193): G1064A; TypeC *~glpT~* (KT372194): Deletion of 248G; TypeD *~glpT~* (KT372195): Insertion of 392T; TypeE *~glpT~* (KT372196): T409C; TypeI*~glpT~* (KT372197): T7A; TypeII*~glpT~* (KT372198): C79T; TypeIII*~glpT~* (KT372201): C299T; TypeIV*~glpT~* (KT372199): G637A; TypeV*~glpT~* (KT372200): G1055A. TypeA*~uhpT~* (KT372202): Deletion of 27T; TypeB*~uhpT~* (KT372203): Insertion of 904T; TypeC*~uhpT~* (KT372204): G1073T; TypeD*~uhpT~* (KT372205): G335A; TypeE*~uhpT~* (KT372206): Deletion of 12 bp from 431A to 442T; TypeF*~uhpT~* (KT372207): G683A; TypeG*~uhpT~* (KT372208): C942A; TypeH*~uhpT~* (KT372209): T1273C.](fmicb-06-01544-g001){#F1}

###### 

Characteristics of MRSA isolates contained *murA* mutations.

  Types of mutation   Strain No.   Mutations in *murA^∗^*        Fosfomycin MIC range (mg/L)   *fosB* gene
  ------------------- ------------ ----------------------------- ----------------------------- -------------
  TypeA*~murA~*       1            T125A (Truncated to 41 aa)    1024                          Negative
  TypeI*~murA~*       1            G193C (Val 65 Leu)            2                             Negative
  TypeII*~murA~*      29           G770A (Gly 257 Asp)           2 \~ \>1024                   Negative
  TypeIII*~murA~*     2            C834A (Asp 278 Glu)           1 \~ 2                        Negative
  TypeIV*~murA~*      7            A873T (Glu 291 Asp)           1 \~ 2                        Negative
  TypeV*~murA~*       1            A1085G (Gln 362 Arg)          2                             Negative
  TypeVI*~murA~*      5            CG1187-1188AT (Thr 396 Asn)   1 \~ 2                        Negative

∗

Deduced amino acid substitutions or sequence variations are shown in brackets.

Mutations in *glpT* and *uhpT* Genes
------------------------------------

Of the 67 fosfomycin-resistant MRSA isolates, 46 contained one of the five different mutations (TypeA--E*~glpT~*) observed in the *glpT* gene. While TypeE*~glpT~* resulted in an amino acid substitution at position 137 (Trp-137→Arg) of GlpT, the other four mutations produced premature stop codons within the *glpT* coding sequence, thereby resulting in the generation of truncated proteins (**Figure [1](#F1){ref-type="fig"}**). In addition, we detected five other mutations within the *glpT* gene that were present only in the fosfomycin-sensitive MRSA isolates. Each of these mutations (TypeI--V*~glpT~*) resulted in amino acid substitutions within the GlpT protein (Supplementary Table [S2](#SM2){ref-type="supplementary-material"} and **Table [4](#T4){ref-type="table"}**).

###### 

Characteristics of fosfomycin-resistant MRSA isolates contained *glpT* and *uhpT* mutations.

  Mutation and its Combination      Strain No.   ST5   ST239            Other ST types                
  --------------------------------- ------------ ----- ---------------- ---------------- -------- --- ------------
  TypeA*~glpT~*                     5            2     1024 \~ \>1024   2                128      1   \>1024
  TypeA*~glpT~* and TypeA*~uhpT~*   1            0     --               0                --       1   \>1024
  TypeA*~glpT~* and TypeB*~uhpT~*   26           25    \>1024           1                1024     0   --
  TypeA*~glpT~* and TypeE*~uhpT~*   1            0     --               1                1024     0   --
  TypeB*~glpT~*                     2            2     64               0                --       0   --
  TypeB*~glpT~* and TypeB*~uhpT~*   1            1     \>1024           0                --       0   --
  TypeB*~glpT~* and TypeC*~uhpT~*   5            5     1024             0                --       0   --
  TypeB*~glpT~* and TypeF*~uhpT~*   1            1     \>1024           0                --       0   --
  TypeC*~glpT~*                     1            1     512              0                --       0   --
  TypeD*~glpT~* and TypeH*~uhpT~*   1            0     --               1                \>1024   0   --
  TypeE*~glpT~* and TypeC*~uhpT~*   1            0     --               1                \>1024   0   --
  TypeE*~glpT~* and TypeG*~uhpT~*   1            0     --               1                1024     0   --
  TypeA*~uhpT~*                     7            3     \>1024           1                128      3   256 \~ 512
  TypeB*~uhpT~*                     5            5     128 \~ \>1024    0                --       0   --
  TypeC*~uhpT~*                     1            1     1024             0                --       0   --
  TypeD*~uhpT~*                     1            0     --               1                \>1024   0   --

Eight distinct mutations were detected in the *uhpT* gene (TypeA--H*~uhpT~*) of the fosfomycin-resistant MRSA isolates. Conversely, no *uhpT* mutations were detected in the fosfomycin-sensitive isolates (Supplementary Table [S3](#SM3){ref-type="supplementary-material"} and **Table [4](#T4){ref-type="table"}**). The TypeC*~uhpT~*, TypeD*~uhpT~*, and TypeH*~uhpT~* mutations led to amino acid substitutions within the UhpT protein, while each of the remaining mutations created premature stop codons within the *uhpT* gene, resulting in the production of truncated protein (**Figure [1](#F1){ref-type="fig"}**).

Molecular Typing
----------------

The 96 MRSA isolates were categorized into 11 ST types, including ST5, ST6, ST30, ST59, ST88, ST121, ST239, ST398, ST764, ST863, and ST2590 (**Table [2](#T2){ref-type="table"}**). Notably, all ST5 strains and 45.7% (16/35) of the ST239 isolates were resistant to fosfomycin (Supplementary Table [S1](#SM1){ref-type="supplementary-material"} and **Table [2](#T2){ref-type="table"}**).

Discussion
==========

The fosfomycin resistance rate of the MRSA isolates examined in this study was approximately 70% (67/96), which was higher than previously detected ([@B9]). In consideration of the average fosfomycin use was as high as 300,977 DDDs (defined daily doses) per year in Shanghai hospitals between 2009 and 2014 (Unpublished data), this elevated resistance rate may have been due to the common usage of this antimicrobial in the region. However, while [@B7] previously detected the *fosB* gene in 46% (18/39) of fosfomycin-resistant *S. aureus* isolates, only 13.4% (9/67) of the strains examined in this study harbored the *fosB* gene. Although this gene was detected only in fosfomycin-resistant isolates, the majority of such isolates were *fosB*-negative, indicating that other mechanisms contribute to fosfomycin resistance in *S. aureus*.

Sequencing analyses detected 25 distinct mutations in the *murA, glpT*, and *uhpT* genes of the MRSA isolates tested (**Figure [1](#F1){ref-type="fig"}** and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Of the seven mutations present in *murA*, 6 (TypeI--VI*~murA~*) were contained by fosfomycin-sensitive isolates, indicating that these modifications did not confer fosfomycin resistance. Also, while the TypeA*~murA~* mutation was only detected in a single fosfomycin-resistant isolate, this strain also harbored mutations within *glpT* and *uhpT*. Thus, it is unclear what role, if any, the TypeA*~murA~* mutation plays in fosfomycin resistance in MRSA.

Each of the *uhpT* mutations (TypeA--H*~uhpT~*) and five of the *glpT* (TypeA--E*~glpT~*) mutations were present only in fosfomycin-resistant isolates. Indeed, approximately 90% (60/67) of the fosfomycin-resistant strains harbored a mutation in *glpT* and/or *uhpT*. Moreover, strains that contained mutations in both *glpT* and *uhpT* exhibited high levels of fosfomycin resistance (MIC \> 1,024 mg/L; **Table [2](#T2){ref-type="table"}**), indicating that each of these 13 mutations might contribute to fosfomycin resistance. In contrast, the remaining five *glpT* mutations (TypeI--V*~glpT~*), which were harbored only by fosfomycin-sensitive strains, likely do not contribute to fosfomycin resistance. Notably, several fosfomycin-resistant isolates were *fosB*-negative, and did not harbor mutations in *murA, glpT*, or *uhpT*. As such, the mechanism that governs fosfomycin resistance in these isolates requires further study.

Multilocus sequence typing analyses indicated that all of the ST5 and 45.7% of the ST239 isolates were resistant to fosfomycin. The majority of the *glpT* and/or *uhpT* mutants were typed as ST5 (**Table [2](#T2){ref-type="table"}**), and several strains harbored identical mutations (**Table [4](#T4){ref-type="table"}**), indicating that clonal dissemination may exist. The first ST5 strain emerged in 2004 (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). The spread of this clone may be associated with the increased occurrence of fosfomycin resistant MRSA. However, fosfomycin resistance-associated mutations were also present in isolates within other STs, suggesting that the emergence of fosfomycin resistance is due to not only clonal dissemination, but also fosfomycin selective pressure on isolates from different clones, and the emergence of spontaneous mutations.

Conclusion
==========

We observed a high rate of fosfomycin resistance in MRSA strains isolated from Shanghai, China. Our findings indicate that mutations within the *glpT* and/or *uhpT* genes play a critical role in conferring this resistance. Thus, the continuous monitoring of fosfomycin susceptibility in *S. aureus*, particularly in MRSA strains is important. Furthermore, our results indicate that caution should be used when employing fosfomycin for the empiric treatment of MRSA infections.
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